slides · global inventory
Chart
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 78,138
Current window 63,811-63,840
Pages 2,605
Rows per page 30
Component
63,811-63,840 of 78,138
66
The chart uses a logarithmic scale on the Y-axis to show exponential growth differences.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
67
The chart illustrates the divergence between traditional CPU scaling and the accelerated growth enabled by AI and specialized hardware.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
83
The slide uses a Gantt-style chart to illustrate the overlap of two batches of targets.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
87
The slide uses a two-step process flow (1 and 2) to explain the technical methodology of their AI-driven drug discovery platform.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
89
SPR stands for Surface Plasmon Resonance. The charts show binding affinity (KD) comparisons.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
96
The chart uses a horizontal bar format to represent development progress. Color coding distinguishes between 'Potential First in Class' (blue) and 'Potential Best in Class' (red).Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
98
The scatter plot shows a Pearson R of 0.74 for N=5389 data points.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
99
The chart is a dot plot showing affinity (KD) vs edit distance from parent binder. The benchmark is a horizontal dashed line.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
102
Includes a Kaplan-Meier survival curve and a biological diagram of TLS.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
105
The slide illustrates a scientific workflow for target discovery.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
106
The chart shows a dose-dependent increase in absorbance for ABS-301 compared to isotype controls, suggesting binding/inhibition activity.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
107
The slide uses a combination of a horizontal bar chart and a data table to quantify the addressable market.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
108
The chart uses a horizontal bar format to represent development progress against a timeline of stages (Target Eval to IND).Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
03
The slide uses a horizontal bar chart to represent the development stage of each program.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
05
The chart plots UC maintenance remission rates against maintenance dosing frequency, showing current standard-of-care drugs clustered at lower efficacy and higher frequency, while the 'Spyre Target' is positioned at higher efficacy and lower frequency.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
The chart uses a horizontal bar representation to indicate progress through discovery and IND-enabling stages.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
18
The slide uses a comparative table for safety metrics and a bar chart for ADA rates to establish clinical equivalence/safety.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
29
The slide uses a stacked bar chart to visualize the additive clinical remission rates, noting a 22% delta between the individual components and the combination.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
03
The slide uses a Gantt-style chart to show the development stage of multiple drug programs.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Situation & Context1 hit
05
The chart is a scatter plot showing maintenance remission rates vs. dosing frequency, positioning current therapies in a cluster and the company's target in a superior quadrant.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
The chart uses a horizontal bar representation to indicate progress through discovery and IND-enabling stages.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
18
The slide uses two distinct data visualizations: a table for clinical safety metrics and a bar chart for ADA rates.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
30
The chart uses a stacked bar to visualize the additive nature of the combination therapy compared to the individual components.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
06
The slide uses a Gantt-style chart to map drug development stages across different indications.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
14
The chart displays longitudinal data for three cell types over 35 days, highlighting the differential pharmacodynamic response.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
19
Includes a swimmer plot (onco-plot) and a summary table of best overall response (BOR) metrics.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
21
Includes a swimmer plot (left) and a summary table (right) with clinical trial metrics.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Loop · Before After1 hit
28
Uses a combination of a scatter plot and biological mechanism diagrams to illustrate the inhibitory effect of IL-18BP.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
33
Includes a bar chart showing dose-dependent PD response in a mouse model and a schematic of the split IL-12 mechanism.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
08
The chart illustrates the revenue contribution of four specific products (VIVITROL, ARISTADA, VUMERITY, LYBALVI) over time.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit